Abstract:Abstract Abstract 140 Background Arsenic trioxide increases the rate of complete remission (CR) and prolongs long-term overall survival in patients with acute promyelocytic leukemia (APL). We demonstrated that an oral arsenic-containing Realgar-Indigo naturalis formula (RIF) could yield clear synergistic effects in an in vivo murine APL model as well as an in vitro APL cell lines. The efficacy and safety of this formula were confirmed by a CR rate of 96.7% and reasonable safety profile in a multicenter Phase II clinical trial in China. To find out whether oral RIF could achieve similar remission and survival with ATO, the Chinese APL Cooperative Group conducted a phase 3 randomized study (APL07) that compared oral RIF with ATO in both the induction and maintenance therapies. Methods In this phase 3 randomized trial, 242 newly diagnosed APL patients were randomly assigned to receive oral RIF (n=121, daily 60 mg per kg body weight) or ATO (n=121, daily 0.15 mg per kg body weight) as a part of induction therapy. All patients also received all-trans-retinoic acid (ATRA; daily 25 mg per square meter) as induction therapy, and were between the ages of 15 and 60 years. After achieving CR, all patients were given three courses of consolidation chemotherapy with anthracycline and cytosine arabinoside. The maintenance treatment included eight cycles of sequential use of ATRA and RIF or ATO for two years. The primary endpoint was disease-free survival (DFS). The secondary endpoints were the rate of CR and overall survival (OS) and safety. Results At a median follow-up of 28 months, no significant differences were noted between RIF group and ATO group with respect to CR rate (99.1% vs.97.2%, P=0.62), DFS (98.9% vs.97.64%, P=0.6) (Figure 1A) and OS at 3 years (99.1% vs.96.6%, P=0.18) (Figure 1B). The rates of adverse events were similar in the two groups. The rate of treatment-related grade 3/4 liver toxic effects was 9.6% in the RIF group and 12.0% in the ATO group(p=0.67). When on the arsenic-containing treatment, the plasma arsenic content was higher in the ATO group than in the RIF group (56.3 vs. 23.6 μg/L, p=0.0002). The median levels of arsenics concentration of plasm, urine, hair and nail samples after completing therapy 12 months were below the lower limit of the normal control. Conclusions Oral Realgar-Indigo naturalis formula yielded a comparable high remission and long-term survival with arsenic trioxide as front-line treatment of newly diagnosed APL. Disclosures: No relevant conflicts of interest to declare.

Single-cell transcriptomics profiling the compatibility mechanism of As 2 O 3 -indigo naturalis formula based on bone marrow stroma cells

Oral Realgar-Indigo Naturalis Formula Achieved Comparably High Rate Of Remission And Survival To Intravenous Arsenic Trioxide As A Front-Line Treatment In Newly Diagnosed Acute Promyelocytic Leukemia: A Multi-Center Randomized Trial Aplo7

Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling.

Dissection of Mechanisms of Chinese Medicinal Formula Realgar-Indigo Naturalis As an Effective Treatment for Promyelocytic Leukemia

Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology

Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway

A Systems Biology Understanding Of The Synergistic Effects Of Arsenic Sulfide And Imatinib In Bcr/Abl-Associated Leukemia

Synergic Effects of Arsenic Trioxide and Camp During Acute Promyelocytic Leukemia Cell Maturation Subtends a Novel Signaling Cross-Talk

Arsenic trioxide, a therapeutic agent for APL.

Arsenic Binding To Rbcc Domain Modulates Oncogenic Pml-Rara And Wild-Type Pml As A Key Molecular Mechanism Of Arsenic Trioxide Treatment For Apl

Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group

Use Of Arsenic Trioxide (As2o3) In The Treatment Of Acute Promyelocytic Leukemia (Apl) .1. As2o3 Exerts Dose-Dependent Dual Effects On Apl Cells

In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (as2o3) in the Treatment of Acute Promyelocytic Leukemia: As2O3 Induces NB4 Cell Apoptosis with Downregulation of Bcl-2 Expression and Modulation of PML-RAR Alpha/pml Proteins

Systems Understanding of Synergism Between As4S4 and Imatinib in Treating BCR/ABL Leukemia Model and in Attenuating BCR/ABL Oncoprotein As Well As Related Regulatory Networks

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin–proteasome pathway

Tetra-arsenic Tetra-Sulfide Enhances NK-92MI Mediated Cellular Immunotherapy in All-Trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia.

CD71-mediated Liposomal Arsenic-nickel Complex Combined with All-trans Retinoic Acid for the efficacy of Acute Promyelocytic Leukemia

Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies